Treatment of acute nonlymphocytic leukemia in adults: Response to 2,2‐anhydro‐1‐B‐D‐Arabinofuranosyl‐5‐fluorocytosine and thioguanine on the L‐12 protocol

Roland Mertelsmann; Robert L. Drapkin; Timothy S. Gee; Sanford Kempin; Sharon Passe; H. Tzvi Thaler; Zalmen Arlin; Monroe Dowling; Peggy Dufour; Susan McKenzie; Lily To; Elber Comacho; Herbert F. Oettgen; Joseph H. Burchenal; Bayard Clarkson

doi:10.1002/1097-0142(19811115)48:10<2136::AID-CNCR2820481003>3.0.CO;2-1

Treatment of acute nonlymphocytic leukemia in adults: Response to 2,2‐anhydro‐1‐B‐D‐Arabinofuranosyl‐5‐fluorocytosine and thioguanine on the L‐12 protocol

Roland Mertelsmann, Robert L. Drapkin, Timothy S. Gee, Sanford Kempin, Sharon Passe, H. Tzvi Thaler, Zalmen Arlin, Monroe Dowling, Peggy Dufour, Susan McKenzie, Lily To, Elber Comacho, Herbert F. Oettgen, Joseph H. Burchenal, Bayard Clarkson

Research output: Contribution to journal › Article › peer-review

7 Scopus citations

Abstract

Fifty‐one adult patients with acute nonlymphocytic leukemia (excluding acute promyelocytic leukemia) were treated on the L‐12 protocol. The L‐12 differed from the preceding L‐6 in that 2,2‐anhydro‐1‐B‐D‐arabinofuranosyl‐5‐fluorocytosine (AAFC), replaced arabinosylcytosine (ara‐C) together with 6‐thioguanine (TG) for remission induction. Achievement of remission was followed by an extended 14‐week multi‐drug consolidation program. With this more intense regimen, an overall complete remission rate of 49% and a median remission duration of 23.7 months were achieved; these results were not significantly better than the 57% complete remission rate and 8.6 months median remission duration obtained with the L‐6 regimen. Four year disease‐free survival was 22% on the L‐12 compared with 16% on the L‐6 protocol. No relationship between prognosis and FAB classification was found on either the L‐6 or the L‐12 protocol.

Original language	English
Pages (from-to)	2136-2142
Number of pages	7
Journal	Cancer
Volume	48
Issue number	10
DOIs	https://doi.org/10.1002/1097-0142(19811115)48:10<2136::AID-CNCR2820481003>3.0.CO;2-1
State	Published - 15 Nov 1981
Externally published	Yes

Access to Document

10.1002/1097-0142(19811115)48:10<2136::AID-CNCR2820481003>3.0.CO;2-1

Cite this

Mertelsmann, R., Drapkin, R. L., Gee, T. S., Kempin, S., Passe, S., Thaler, H. T., Arlin, Z., Dowling, M., Dufour, P., McKenzie, S., To, L., Comacho, E., Oettgen, H. F., Burchenal, J. H., & Clarkson, B. (1981). Treatment of acute nonlymphocytic leukemia in adults: Response to 2,2‐anhydro‐1‐B‐D‐Arabinofuranosyl‐5‐fluorocytosine and thioguanine on the L‐12 protocol. Cancer, 48(10), 2136-2142. https://doi.org/10.1002/1097-0142(19811115)48:10<2136::AID-CNCR2820481003>3.0.CO;2-1

@article{82af6eefad5f4b389466803a38cfab55,

title = "Treatment of acute nonlymphocytic leukemia in adults: Response to 2,2‐anhydro‐1‐B‐D‐Arabinofuranosyl‐5‐fluorocytosine and thioguanine on the L‐12 protocol",

abstract = "Fifty‐one adult patients with acute nonlymphocytic leukemia (excluding acute promyelocytic leukemia) were treated on the L‐12 protocol. The L‐12 differed from the preceding L‐6 in that 2,2‐anhydro‐1‐B‐D‐arabinofuranosyl‐5‐fluorocytosine (AAFC), replaced arabinosylcytosine (ara‐C) together with 6‐thioguanine (TG) for remission induction. Achievement of remission was followed by an extended 14‐week multi‐drug consolidation program. With this more intense regimen, an overall complete remission rate of 49% and a median remission duration of 23.7 months were achieved; these results were not significantly better than the 57% complete remission rate and 8.6 months median remission duration obtained with the L‐6 regimen. Four year disease‐free survival was 22% on the L‐12 compared with 16% on the L‐6 protocol. No relationship between prognosis and FAB classification was found on either the L‐6 or the L‐12 protocol.",

author = "Roland Mertelsmann and Drapkin, {Robert L.} and Gee, {Timothy S.} and Sanford Kempin and Sharon Passe and Thaler, {H. Tzvi} and Zalmen Arlin and Monroe Dowling and Peggy Dufour and Susan McKenzie and Lily To and Elber Comacho and Oettgen, {Herbert F.} and Burchenal, {Joseph H.} and Bayard Clarkson",

year = "1981",

month = nov,

day = "15",

doi = "10.1002/1097-0142(19811115)48:10<2136::AID-CNCR2820481003>3.0.CO;2-1",

language = "English",

volume = "48",

pages = "2136--2142",

journal = "Cancer",

issn = "0008-543X",

publisher = "John Wiley & Sons Inc.",

number = "10",

}

Mertelsmann, R, Drapkin, RL, Gee, TS, Kempin, S, Passe, S, Thaler, HT, Arlin, Z, Dowling, M, Dufour, P, McKenzie, S, To, L, Comacho, E, Oettgen, HF, Burchenal, JH & Clarkson, B 1981, 'Treatment of acute nonlymphocytic leukemia in adults: Response to 2,2‐anhydro‐1‐B‐D‐Arabinofuranosyl‐5‐fluorocytosine and thioguanine on the L‐12 protocol', Cancer, vol. 48, no. 10, pp. 2136-2142. https://doi.org/10.1002/1097-0142(19811115)48:10<2136::AID-CNCR2820481003>3.0.CO;2-1

TY - JOUR

T1 - Treatment of acute nonlymphocytic leukemia in adults

T2 - Response to 2,2‐anhydro‐1‐B‐D‐Arabinofuranosyl‐5‐fluorocytosine and thioguanine on the L‐12 protocol

AU - Mertelsmann, Roland

AU - Drapkin, Robert L.

AU - Gee, Timothy S.

AU - Kempin, Sanford

AU - Passe, Sharon

AU - Thaler, H. Tzvi

AU - Arlin, Zalmen

AU - Dowling, Monroe

AU - Dufour, Peggy

AU - McKenzie, Susan

AU - To, Lily

AU - Comacho, Elber

AU - Oettgen, Herbert F.

AU - Burchenal, Joseph H.

AU - Clarkson, Bayard

PY - 1981/11/15

Y1 - 1981/11/15

N2 - Fifty‐one adult patients with acute nonlymphocytic leukemia (excluding acute promyelocytic leukemia) were treated on the L‐12 protocol. The L‐12 differed from the preceding L‐6 in that 2,2‐anhydro‐1‐B‐D‐arabinofuranosyl‐5‐fluorocytosine (AAFC), replaced arabinosylcytosine (ara‐C) together with 6‐thioguanine (TG) for remission induction. Achievement of remission was followed by an extended 14‐week multi‐drug consolidation program. With this more intense regimen, an overall complete remission rate of 49% and a median remission duration of 23.7 months were achieved; these results were not significantly better than the 57% complete remission rate and 8.6 months median remission duration obtained with the L‐6 regimen. Four year disease‐free survival was 22% on the L‐12 compared with 16% on the L‐6 protocol. No relationship between prognosis and FAB classification was found on either the L‐6 or the L‐12 protocol.

AB - Fifty‐one adult patients with acute nonlymphocytic leukemia (excluding acute promyelocytic leukemia) were treated on the L‐12 protocol. The L‐12 differed from the preceding L‐6 in that 2,2‐anhydro‐1‐B‐D‐arabinofuranosyl‐5‐fluorocytosine (AAFC), replaced arabinosylcytosine (ara‐C) together with 6‐thioguanine (TG) for remission induction. Achievement of remission was followed by an extended 14‐week multi‐drug consolidation program. With this more intense regimen, an overall complete remission rate of 49% and a median remission duration of 23.7 months were achieved; these results were not significantly better than the 57% complete remission rate and 8.6 months median remission duration obtained with the L‐6 regimen. Four year disease‐free survival was 22% on the L‐12 compared with 16% on the L‐6 protocol. No relationship between prognosis and FAB classification was found on either the L‐6 or the L‐12 protocol.

UR - http://www.scopus.com/inward/record.url?scp=0019809037&partnerID=8YFLogxK

U2 - 10.1002/1097-0142(19811115)48:10<2136::AID-CNCR2820481003>3.0.CO;2-1

DO - 10.1002/1097-0142(19811115)48:10<2136::AID-CNCR2820481003>3.0.CO;2-1

M3 - Article

C2 - 6170414

AN - SCOPUS:0019809037

VL - 48

SP - 2136

EP - 2142

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 10

ER -

Treatment of acute nonlymphocytic leukemia in adults: Response to 2,2‐anhydro‐1‐B‐D‐Arabinofuranosyl‐5‐fluorocytosine and thioguanine on the L‐12 protocol

Abstract

Access to Document

Fingerprint

Cite this